Latest News and Press Releases

YARDLEY, Pa., June 24, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be...

Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...

YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company...

Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 41st Annual Health Care Conference on March 4, 2021 YARDLEY, Pa., Feb. 17, 2021 ...

YARDLEY, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...

YARDLEY, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...

YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...